Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18286467 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Charych DH, et al. (2008) Inhibition of Cdc7/Dbf4 kinase activity affects specific phosphorylation sites on MCM2 in cancer cells. J Cell Biochem 104, 1075-86 18286467
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S31-p - MCM2 (human) ▲
Orthologous residues
MCM2 (human): S31‑p, MCM2 (mouse): S31‑p, MCM2 (rat): S32‑p
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CDC7 (human)

S40-p - MCM2 (human) ▲
Orthologous residues
MCM2 (human): S40‑p, MCM2 (mouse): S40‑p, MCM2 (rat): S41‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry, phospho-antibody
 Disease tissue studied:  lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary)
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CDC7 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDC7 (human) siRNA inhibition of enzyme siRNA knockdown CDC7 or its cofactor Dbf4
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA decrease

S53-p - MCM2 (human) ▲
Orthologous residues
MCM2 (human): S53‑p, MCM2 (mouse): S53‑p, MCM2 (rat): S54‑p
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CDC7 (human)

S108-p - MCM2 (human) ▲
Orthologous residues
MCM2 (human): S108‑p, MCM2 (mouse): S108‑p, MCM2 (rat): S109‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, mass spectrometry, phospho-antibody
 Disease tissue studied:  lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary)
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CDC7 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CDC7 (human) siRNA inhibition of enzyme siRNA knockdown CDC7 or its cofactor Dbf4
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA decrease

S139-p - MCM2 (human) ▲
Orthologous residues
MCM2 (human): S139‑p, MCM2 (mouse): S139‑p, MCM2 (rat): S140‑p
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CDC7 (human)

S220-p - MCM2 (human) ▲
Orthologous residues
MCM2 (human): S220‑p, MCM2 (mouse): S220‑p, MCM2 (rat): S221‑p
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CDC7 (human)


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.